Cargando…

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention

This study aims to determine whether genetic variants that influence CYP3A4 expression are associated with platelet reactivity in clopidogrel-treated patients undergoing elective percutaneous coronary intervention (PCI), and to evaluate the influence of statin/fibrate co-medication on these associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergmeijer, Thomas O., Yasmina, Alfi, Vos, Gerrit J. A., Janssen, Paul W. A., Hackeng, Christian M., Kelder, Johannes C., Verma, Shefali S., Ritchie, Marylyn D., Gong, Li, Klein, Teri E., de Boer, Anthonius, Klungel, Olaf H., ten Berg, Jurriën M., Deneer, Vera H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564055/ https://www.ncbi.nlm.nih.gov/pubmed/32932966 http://dx.doi.org/10.3390/genes11091068

Ejemplares similares

Patterns of antiplatelet drug use after a first myocardial infarction during a 10‐year period
por: Yasmina, Alfi, et al.
Publicado: (2016)

Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment
por: Bergmeijer, Thomas O., et al.
Publicado: (2018)

Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome
por: van den Broek, Wout W A, et al.
Publicado: (2022)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials
por: van den Broek, Wout W. A., et al.
Publicado: (2023)

Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial
por: Gimbel, Marieke E., et al.
Publicado: (2020)

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
por: Verma, Shefali Setia, et al.
Publicado: (2020)

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
por: Azzahhafi, Jaouad, et al.
Publicado: (2022)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients
por: Godschalk, Thea Cornelia, et al.
Publicado: (2012)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Another Round of “Clue” to Uncover the Mystery of Complex Traits
por: Verma, Shefali Setia, et al.
Publicado: (2018)

The Risk of Bleeding and Adverse Events with Clopidogrel in Elective Hip and Knee Arthroplasty Patients
por: Wu, Cheng-Ta, et al.
Publicado: (2022)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

PharmCAT: A Pharmacogenomics Clinical Annotation Tool
por: Klein, Teri E., et al.
Publicado: (2017)

Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study
por: Eroglu, Talip E., et al.
Publicado: (2022)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
por: Li, Changqing, et al.
Publicado: (2021)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing
por: Willemsen, Laura M., et al.
Publicado: (2021)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
por: Mirabbasi, Seyed abbas, et al.
Publicado: (2017)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021)

Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients
por: Olie, Renske H., et al.
Publicado: (2021)

Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study
por: Wykrzykowska, Joanna J., et al.
Publicado: (2009)

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
por: Kreutz, Rolf P, et al.
Publicado: (2013)

Discovery of Ancestry-specific Variants Associated with Clopidogrel Response among Caribbean Hispanics
por: Yang, Guang, et al.
Publicado: (2023)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients
por: Ahmed, Sagheer, et al.
Publicado: (2022)

Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges
por: Shah, Manish B.
Publicado: (2022)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
por: Shi, Hong Ting, et al.
Publicado: (2021)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

What Can We Learn from the Past by Means of Very Long-Term Follow-Up after Aortic Valve Replacement?
por: Swinkels, Ben, et al.
Publicado: (2021)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
por: Sukasem, Chonlaphat, et al.
Publicado: (2013)

Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy
por: Tajima, Hayato, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t1h7trm4ms4cdrqiffc0lihmv5